Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Vespula germanica venom protein

    go.drugbank.com/drugs/DB11030
    Approved

    Vespula germanica venom protein is an extract of Vespula germanica venom. Vespula germanica venom protein is used in allergenic testing.

  2. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … It suppresses CMV replication through selective inhibition of viral DNA synthesis.

    Products: SIDOVIS 375 MG/5 ML KONSANTRE INFÜZYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADET
  3. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis

  4. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. … The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury

    Mixtures: FEEL 360 DES, ANTIFLU-DES
  5. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    It plays an essential role as an antioxidant in neutralizing food allergens and redox signalling. Allergens containing disulfide bonds are inactivated when reduced by thioredoxin. … It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site.

  6. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Currently dehydroascorbic acid is an experimental drug with no known approved indications. … Dehydroascorbic acid is made from the oxidation of ascorbic acid. This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid.

    Categories: Diet, Food, and Nutrition
  7. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood. … Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic

    Categories: Drugs for Treatment of Bone Diseases
  8. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    However, many strains of an individual species may be resistant. … Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase.

    Categories: combinations of sulfonamides
  9. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  10. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).

    Products: Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET, SKYRİZİ 150 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET